• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

GW Pharmaceuticals - Articles and news items

cannabis-cover

New Colombia Resources collaborate with AiP seeking FDA approval for medical cannabis product

Industry news / 17 October 2016 / Niamh Louise Marriott, Digital Content Producer

The Ministry has publicly expressed interest in bringing Cannabis research to Colombia and the Company feels their project is in line with this aspiration…

Infantile Spasms

Infantile spasms selected as 4th target indication for Epidiolex

Industry news / 21 June 2016 / Victoria White, Digital Content Producer

GW Pharmaceuticals has selected infantile spasms as the fourth target indication for its Epidiolex orphan paediatric epilepsy development programme…

Epidiolex

Phase III trial of GW’s Epidiolex in TSC commences

Industry news / 11 April 2016 / Victoria White, Digital Content Producer

TSC is the third indication that GW is targeting with Epidiolex, which includes four Phase III trials in Dravet syndrome and Lennox-Gastaut syndrome…

Infantile Spasms

GW announces positive results for Epidiolex in Dravet syndrome

Industry news / 14 March 2016 / Victoria White

Epidiolex achieved the primary endpoint of a significant reduction in convulsive seizures assessed over the entire treatment period compared with placebo…

cbd

GW announces positive top line results for CBD in schizophrenia

Industry news / 15 September 2015 / Victoria White

The addition of Cannabidiol (CBD)to the medication of patients who were only partially responsive to standard treatment produced significant improvements in outcome measures…

epidiolex

GW commences Phase 3 trial of Epidiolex for the treatment of Lennox-Gastaut syndrome

Industry news / 12 May 2015 / Victoria White

GW Pharmaceuticals has commenced a Phase 3 clinical trial of Epidiolex (cannabidiol or CBD) for the treatment of Lennox-Gastaut syndrome (LGS)…

perampanel

GW initiates second Phase 3 trial of Epidiolex in Dravet syndrome

Industry news / 22 April 2015 / Victoria White

GW Pharmaceuticals has initiated the second Phase 3 clinical trial of Epidiolex for the treatment of Dravet syndrome, a rare form of childhood epilepsy…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +